Codexis appoints Christos Richards to Board of Directors

CODEXIS, INC.

Appointment effective January 14, 2025 as Class II director with term until 2027 annual meeting.
Richards is independent under Nasdaq rules; will serve on Nominating and Governance and Strategy Committees.
Annual cash retainer of $50,000 plus $10,000 each for committee service; initial RSU grant of $200,000 vesting over three years.
Richards brings executive search and biopharma board experience, previously on Coherus BioSciences board.
No arrangements or transactions with the company other than standard director compensation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christos Richards

Director

CDXS · CODEXIS, INC.

Effective: 2025-01-14
Filed: January 16, 2025, 6:59 PM ET

On January 14, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee (the “Nominating and Corporate Governance Committee”), appointed Christos Richards as a member of the Board as a Class II director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Christos Richards was appointed as Director at CODEXIS, INC..

Action: appointed
Role: Director

Exact text from the filing

On January 14, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee (the “Nominating and Corporate Governance Committee”), appointed Christos Richards as a member of the Board as a Class II director, effective immediately.

View on SEC.gov

CODEXIS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-007775

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.